Patient and Provider Perspectives on Genetic Risk Profiling

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18-100
SponsorRoyal Marsden NHS Foundation Trust

About this trial

A qualitative interview study exploring the patient and provider perspectives on the clinical utility of genetic risk profiling in routine clinical practice. The findings from the study may contribute towards future research and informing clinical practice.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Individuals assigned male at birth who are aged 18 and over and who have capacity to consent

Patients who have undergone genetic risk profiling for prostate cancer and have received their results

Individuals from diverse backgrounds (age, ethnicity, risk status, etc)

Healthcare providers who have delivered a genetic risk profiling result for prostate cancer

Disqualifiers

Individuals who lack capacity to consent

Individuals deemed unsuitable to recruit based on their poor performance status or current medical condition

Trial population

Patients who have undergone and received a genetic risk profiling result for prostate cancer and healthcare providers who have delivered a genetic risk profiling result for prostate cancer

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Qualitative interview

    Other intervention

    Interview of participants to gain perspectives and experiences

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: Patient participants1 intervention
Group B: Provider participants1 intervention

Trial outcomes

Primary outcomes

1

Data pertaining to the experiences and perspectives of healthcare providers and patients regarding the clinical utility of genetic risk profiling in routine clinical practice, using a qualitative (interview) thematic analysis approach.

The study findings will provide data pertaining to the current experiences, perspectives, benefits, limitations and challenges patients and providers encounter when receiving and delivering genetic risk profiling results. The findings can help to highlight areas of concern which need to be addressed, improved and/or implemented prior to clinical implementation of genetic risk profiling into routine clinical care. The findings can also identify the educational, clinical and/or support needs and may also highlight aspects of clinical care which need to be improved or established (e.g. screening guidelines, resources, upskilled workforce) prior to the integration of genetic risk profiling into routine clinical practice. This will ensure that genetic risk profiling is relevant and feasible in terms of improving the clinical care and health seeking behaviours of patients.

Time frame
January 2026 to August 2027

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Royal Marsden NHS Foundation Trust

Lead sponsor

Institute of Cancer Research, United Kingdom

Collaborator